Comprehensive Update of the New and Emerging Therapies for the Treatment of Multiple Myeloma

September 10, 2020 • 6:00 PM ET

CLICK TO REGISTER
https://event.on24.com/wcc/r/2600405/7E37C8C432791FFAB4AEF878236E7544

FACULTY
Jordan A. Miller, PharmD, BCPS, BCOP, CPP
Clinical Pharmacist Practitioner, Myeloma & Lymphoma Department of Pharmacy
University of North Carolina Medical Center
Chapel Hill, North Carolina

EDUCATIONAL OBJECTIVES

• Describe the mechanisms of action for the new and emerging drug classes used for the treatment of multiple myeloma and the associated dosage forms of those medications
• Determine appropriate drug therapy for a patient with relapsed or refractory disease based on prior treatment regimens and patient-specific factors
• Develop a management strategy to improve adherence for a patient receiving a combination of oral and IV therapies for the treatment of multiple myeloma

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-236-L01-P. The activity is available for CE credit through January 19, 2021.

Type of Activity: Application

This activity is supported by educational grants from GlaxoSmithKline, Takeda, Karyopharm, and Amgen.

For more CE opportunities, please visit:
www.pharmacytimes.org

Faculty disclosures will be provided prior to the presentation.